Spectral Med Inc surprised investors with a significant earnings beat, showcasing resilience in a challenging market.
Recent earnings trend
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 โ C$1.51 |
| 60 trading days | C$1.37 | C$1.20 โ C$1.56 |
| 90 trading days | C$1.36 | C$1.16 โ C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.
Beat estimates in 2 of the last 4 comparable quarter(s).
| Fiscal period | Report date | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-06 | โ | -0.0100 | โ |
| 2026-06-30 | 2026-08-07 | 0.0011 | -0.0100 | +111.0% |
| 2026-03-31 | 2026-05-08 | -0.0100 | -0.0100 | +0.0% |
| 2025-12-31 | 2026-03-26 | -0.0100 | -0.0200 | +50.0% |
| 2025-09-30 | 2025-11-07 | -0.1100 | -0.0100 | -1000.0% |
| 2025-06-30 | 2025-08-08 | -0.0068 | โ | โ |
On August 7, 2026, Spectral Med Inc (EDT.TO) reported its fiscal second-quarter earnings for the period ending June 30, 2026. The company delivered an EPS of 0.0011, beating the consensus estimate of -0.01 by an impressive 111.0%. This marks a notable achievement for the company amidst fluctuating market conditions.
Investor takeaway: Investors should take note of Spectral Med's ability to exceed earnings expectations, which could signal potential growth and strategic advancements in the biotechnology sector. However, the company's historical EPS trends warrant a cautious approach.
EPS Surprise of 111.0%
Spectral Med's EPS of 0.0011 significantly exceeded the estimated loss of -0.01, reflecting a strong operational performance in the quarter.
Advertisement
Bull case
The successful filing of the PMA application for its PMX device with the U.S. FDA, along with positive trial results, puts Spectral Med in a strong position for potential commercial success. This could boost investor confidence and lead to future revenue growth.
Bear case
Despite the recent earnings beat, the company's historical EPS trends show volatility, and its profit margin remains at 0.00%. Investors should stay alert to the potential risks tied to its operational and regulatory challenges.
Earnings Overview
โ
Revenue and Margins
โ
Analyst Price Targets
โ
Wealth Awesome Price Forecast
โ
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
